Dexcom (DXCM) Receivables (2010 - 2026)

Dexcom (DXCM) has 17 years of Receivables data on file, last reported at $1.1 billion in Q1 2026.

• On a quarterly basis, Receivables fell 5.5% year-over-year to $1.1 billion in Q1 2026; TTM through Mar 2026 was $1.1 billion, a 5.5% decrease from a year earlier, with the FY2025 full-year figure at $1.2 billion, up 19.7% from the prior year.
• Receivables for Q1 2026 stood at $1.1 billion, down from $1.2 billion in the prior quarter.
• Over the last five years, Receivables for DXCM reached as high as $1.4 billion in Q2 2025 and fell as low as $554.8 million in Q1 2022.
• Historically, Receivables has averaged $917.6 million across 5 years, with a median of $981.9 million in 2023.
• Across the five-year window, Receivables jumped 53.12% in 2024 and declined 5.5% in 2026, its largest moves.
• Year by year, Receivables stood at $722.3 million in 2022, then soared by 35.94% to $981.9 million in 2023, then grew by 4.91% to $1.0 billion in 2024, then gained by 19.7% to $1.2 billion in 2025, then retreated by 10.34% to $1.1 billion in 2026.
• Per Business Quant data, the three most recent Receivables figures were $1.1 billion in Q1 2026, $1.2 billion in Q4 2025, and $1.1 billion in Q3 2025.